<DOC>
	<DOCNO>NCT00303108</DOCNO>
	<brief_summary>The purpose study determine ORR associate Doxil combination carboplatin HER2- ( negative ) MBC ( Herceptin HER2+ MBC ) .</brief_summary>
	<brief_title>Doxil &amp; Carboplatin Plus HER2+ Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Has metastatic breast cancer document HER2 HER2+ ( IHC3+ FISH+ ) disease Has measurable MBC , least 1 measurable lesion per RECIST criterion ( see Section 10 ) . Irradiated lesion use assess response use assess progression . Has prior treatment Doxil carboplatin ; may adjuvant Herceptin treatment complete 1 year prior study Has adjuvant chemotherapy within 1 year prior study , may receive prior anthracyclines adjuvant chemotherapy For taxanepretreated patient ( adjuvant metastatic ) , 1 prior chemotherapy regimen MBC For taxanena√Øve patient , prior chemotherapy MBC Has cumulative dos &lt; 300 mg/m2 prior doxorubicin &lt; 450 mg/m2 prior epirubicin Has normal cardiac function evidence LVEF within institutional normal limit multiple gated acquisition ( MUGA ) scan . An echocardiogram ( ECHO ) may use MUGA available , test must use throughout study evaluate LVEF . Has ECOG Performance Status ( PS ) 02 ( see Appendix I ) Is male female great equal 18 year age Laboratory Values Please refer protocol section 4.2 specific laboratory value . Has negative serum pregnancy test within 7 day prior registration ( woman childbearing potential [ WOCBP ; surgically sterilize menarche 1 year postmenopause ] ) If fertile , patient ( male female ) agree use acceptable method birth control ( eg , abstinence , intrauterine device , oral contraceptive , barrier device spermicide surgical sterilization ) avoid pregnancy duration study period 3 month thereafter . Has sign Patient Informed Consent Form Has sign Patient Authorization Form ( HIPAA Form ) Has life expectancy &gt; 3 month Has myocardial infarction ( MI ) within 6 month trial enrollment , New York Heart Association ( NYHA ; see Appendix IV ) Class II great heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , clinically significant pericardial disease , electrocardiographic evidence acute ischemic active conduction system abnormalities Has history hypersensitivity reaction attribute conventional formulation doxorubicin HCL component Doxil Has evaluable disease ; eg , bone , pleural , peritoneal disease Is receive concurrent immunotherapy , hormonal therapy , radiation therapy . Patients receive immunosuppressant therapy autoimmune disease may enroll trial drug washout period 2 week . Is receive concurrent investigational therapy receive therapy within 30 day Has evidence brain metastasis require steroid and/or radiation document leptomeningeal disease Has serious uncontrolled intercurrent medical psychiatric illness , include serious infection history uncontrolled seizure , CNS disorder deem Treating Physician clinically significant , preclude inform consent Has history malignancy within last 5 year ( except cure basal cell carcinoma skin carcinoma situ uterine cervix ) , could affect diagnosis assessment study drug Is pregnant lactate woman Is unable comply requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>